PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Pelthos Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$20.26+0.11 (+0.55%)
Close on Oct 19, 2026
- Market cap
- $71.71M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$8.74 (−30.14%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Pelthos Therapeutics Inc. reported revenue of $43.30M for the twelve months to Jun 30, 2026. Free cash flow was -$22.69M.
Revenue
$43.30M
TTM Q2 2026
Operating income
-$57.78M
TTM Q2 2026
Free cash flow
-$22.69M
FY2025
EPS, diluted
-$26.30
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $71.71M
- P/E ratio
- –
- Price to sales
- 1.66
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -31.64%
Fundamentals
- Revenue
- $43.30M
- Net income
- -$86.39M
- EPS, diluted
- -$26.30
- Free cash flow
- -$22.69M
- Book value per share
- -$0.42
- Diluted shares
- 4M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
$43.30M
Gross profit
$34.03M
Operating income
-$57.78M
Net income
-$86.39M
EPS, diluted
-$26.30
Free cash flow
–
Reported periodTrailing twelve months